Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameMabpharm-B
Stock Code02181
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities专注于治疗癌症和自身免疫性疾病的新药及生物类似药的研发和生产
Listing Date2019-05-31
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)泰州中国医药城口泰路西侧陆家路东侧G79幢
Business Address (Hong Kong)新界沙田香港科学园二期尚湖楼7楼713单位
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitemabpharm.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 1.50 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-05-20 to 2019-05-24
Global Offering Shares783,580,000 shares
HK Public Offer Shares (Initial)78,358,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)705,222,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO4,124,080,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share16.7%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,175,370,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.91B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +409%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损约人民币149.8百万元
Period-End Cash Balance人民币198.2百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20172018
Revenue 4,79824,059
Cost of sales -307-12,507
Administrative expenses -24,900-42,128
Net finance costs -3,328-4,481
Profit before tax -47,706-152,593
Income tax expense 0-2,834
Profit for the year -47,706-149,759
Profit attributable to owners -31,064-124,883
Balance Sheet
Item 20172018
Cash and cash equivalents 76,443198,195
Inventories 36,31927,551
Total current assets 154,935260,753
Total current liabilities 70,853156,450
Total equity 153,289249,572
Equity attributable to owners 99,813249,572
Interest-bearing borrowings 75,000105,000
Cash Flow Statement
Item 20172018
Net cash from operating activities -65,122-61,874
Net cash from investing activities -13,597-82,706
Net cash from financing activities 16,897256,819
Net increase in cash -61,822112,239
Depreciation of PP&E 10,08011,716
Purchase of PP&E -13,129-49,787
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.21
First Day OpenHK$ 1.5
First Day Change-19.33%
First Day Volume167506000.0
First Day Turnover215606000.0
Use of Proceeds
1、約70.1%或748.7百萬港元將用于我們的核心候選產品CMAB007、CMAB008及CMAB009; 2、約20.1%或214.7百萬港元將用于我們其他候選產品的研發活動; 3、約9.8%或104.7百萬港元將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 三生制药 196,227,000 HKD — 16.69% — 6 months 2019-11-30

Directors & Management

PositionChinese nameEnglish Name
Chairman焦树阁—
Company Secretary李云峰、曾浩贤—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股东郭建军先生(透过Asia Mabtech及United Circuit合共持有约54.00%),CDH PE持有18.00%,FH Investment持有5.18%
About this page

This page shows Mabpharm-B (02181) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect